Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer.
暂无分享,去创建一个
W. Woodward | T. Buchholz | V. Valero | S. Krishnamurthy | W. Yang | A. Lucci | N. Ueno | A. González-Angulo | M. Bondy | P. Allen | M. Cristofanilli | Y. Gong | J. Willey | T. Yu | Jing Li
[1] R. Kay. The Analysis of Survival Data , 2012 .
[2] E. Elkin,et al. Locoregional outcomes of inflammatory breast cancer patients treated with standard fractionation radiation and daily skin bolus in the taxane era. , 2010, International journal of radiation oncology, biology, physics.
[3] H. Gogas,et al. Paclitaxel and carboplatin as neoadjuvant chemotherapy in patients with locally advanced breast cancer: A phase II Trial of the Hellenic Cooperative Oncology Group. , 2010, Clinical breast cancer.
[4] T. Nielsen,et al. Breast cancer subtypes and the risk of local and regional relapse. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] W. Woodward,et al. Estrogen/progesterone receptor negativity and HER2 positivity predict locoregional recurrence in patients with T1a,bN0 breast cancer. , 2009, International journal of radiation oncology, biology, physics.
[6] Funda Meric-Bernstam,et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] John Quackenbush,et al. Identification of Novel Kinase Targets for the Treatment of Estrogen Receptor–Negative Breast Cancer , 2009, Clinical Cancer Research.
[8] L. Carey,et al. Breast cancer molecular subtypes in patients with locally advanced disease: impact on prognosis, patterns of recurrence, and response to therapy. , 2009, Seminars in radiation oncology.
[9] S. O'toole,et al. Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] J. Inoue,et al. Constitutive activation of nuclear factor‐κB is preferentially involved in the proliferation of basal‐like subtype breast cancer cell lines , 2009, Cancer science.
[11] Adam M. Gustafson,et al. An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer , 2009, Breast Cancer Research.
[12] P. Levine,et al. Essential role for eIF4GI overexpression in the pathogenesis of inflammatory breast cancer , 2009, Nature Cell Biology.
[13] Charles M. Perou,et al. Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer , 2009, Journal of the National Cancer Institute.
[14] J. Kurebayashi. Possible treatment strategies for triple-negative breast cancer on the basis of molecular characteristics , 2009, Breast cancer.
[15] A. Nobel,et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] S. Merajver,et al. Molecular determinants of the inflammatory breast cancer phenotype. , 2008, Oncology.
[17] W. Woodward,et al. Locoregional treatment outcomes after multimodality management of inflammatory breast cancer. , 2008, International journal of radiation oncology, biology, physics.
[18] T. Nielsen,et al. The combination of high cyclin E and Skp2 expression in breast cancer is associated with a poor prognosis and the basal phenotype. , 2008, Human pathology.
[19] Barbara L. Smith,et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] F. B. Sørensen,et al. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] Samuel Leung,et al. Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype , 2008, Clinical Cancer Research.
[22] G. Hortobagyi,et al. Trends for inflammatory breast cancer: is survival improving? , 2007, The oncologist.
[23] A. Nobel,et al. The molecular portraits of breast tumors are conserved across microarray platforms , 2006, BMC Genomics.
[24] P. Dam,et al. Identification of cell-of-origin breast tumor subtypes in inflammatory breast cancer by gene expression profiling , 2006, Breast Cancer Research and Treatment.
[25] Daniel Birnbaum,et al. Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. , 2005, Cancer research.
[26] T. Buchholz,et al. Inflammatory breast cancer: current concepts in local management. , 2005, Breast disease.
[27] A. Gown,et al. Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma , 2004, Clinical Cancer Research.
[28] S. Merajver,et al. WISP3 and RhoC guanosine triphosphatase cooperate in the development of inflammatory breast cancer , 2003, Breast Cancer Research.
[29] R. Tibshirani,et al. Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[30] R. Tibshirani,et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[31] S. Merajver,et al. Persistent E-Cadherin Expression in Inflammatory Breast Cancer , 2001, Modern Pathology.
[32] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[33] S. Singletary,et al. Locoregional irradiation for inflammatory breast cancer: effectiveness of dose escalation in decreasing recurrence. , 2000, International journal of radiation oncology, biology, physics.
[34] T. Buchholz,et al. Frequency of first metastatic events in breast cancer: implications for sequencing of systemic and local-regional treatment. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] S. Merajver,et al. A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[36] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .